Following the discovery that mutant KRAS tumors were resistant to anti-EGFR antibodies, patients with metastatic colorectal cancer are now recommended to detect the KRAS codons12 and 13 mutation status before MoAbs therapy [8], [17], [18]. Here, EGFR is linked to metastatic colorectal cancer.